vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and WAFD INC (WAFD). Click either name above to swap in a different company.

WAFD INC is the larger business by last-quarter revenue ($191.4M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). WAFD INC runs the higher net margin — 33.5% vs -5.5%, a 39.1% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.8%). WAFD INC produced more free cash flow last quarter ($50.0M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 5.5%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

Washington Federal Bank is a bank based in Seattle, Washington. It operates 210 branches in Washington, Oregon, Idaho, Nevada, Utah, Arizona, New Mexico, California, and Texas. It is on the list of largest banks in the United States.

TARS vs WAFD — Head-to-Head

Bigger by revenue
WAFD
WAFD
1.3× larger
WAFD
$191.4M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+116.6% gap
TARS
128.4%
11.8%
WAFD
Higher net margin
WAFD
WAFD
39.1% more per $
WAFD
33.5%
-5.5%
TARS
More free cash flow
WAFD
WAFD
$37.1M more FCF
WAFD
$50.0M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
5.5%
WAFD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
TARS
TARS
WAFD
WAFD
Revenue
$151.7M
$191.4M
Net Profit
$-8.4M
$64.2M
Gross Margin
Operating Margin
-5.3%
43.0%
Net Margin
-5.5%
33.5%
Revenue YoY
128.4%
11.8%
Net Profit YoY
63.8%
35.8%
EPS (diluted)
$-0.17
$0.79

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
WAFD
WAFD
Q4 25
$151.7M
$191.4M
Q3 25
$118.7M
$188.3M
Q2 25
$102.7M
$186.3M
Q1 25
$78.3M
$179.8M
Q4 24
$66.4M
$171.1M
Q3 24
$48.1M
$188.7M
Q2 24
$40.8M
$194.4M
Q1 24
$27.6M
$172.0M
Net Profit
TARS
TARS
WAFD
WAFD
Q4 25
$-8.4M
$64.2M
Q3 25
$-12.6M
$60.6M
Q2 25
$-20.3M
$62.0M
Q1 25
$-25.1M
$56.3M
Q4 24
$-23.1M
$47.3M
Q3 24
$-23.4M
$61.1M
Q2 24
$-33.3M
$64.6M
Q1 24
$-35.7M
$15.9M
Operating Margin
TARS
TARS
WAFD
WAFD
Q4 25
-5.3%
43.0%
Q3 25
-12.2%
41.2%
Q2 25
-21.6%
42.8%
Q1 25
-33.5%
40.1%
Q4 24
-36.8%
35.2%
Q3 24
-52.3%
42.8%
Q2 24
-81.6%
42.6%
Q1 24
-136.5%
12.2%
Net Margin
TARS
TARS
WAFD
WAFD
Q4 25
-5.5%
33.5%
Q3 25
-10.6%
32.2%
Q2 25
-19.8%
33.3%
Q1 25
-32.1%
31.3%
Q4 24
-34.8%
27.6%
Q3 24
-48.7%
32.4%
Q2 24
-81.6%
33.2%
Q1 24
-129.4%
9.2%
EPS (diluted)
TARS
TARS
WAFD
WAFD
Q4 25
$-0.17
$0.79
Q3 25
$-0.30
$0.71
Q2 25
$-0.48
$0.73
Q1 25
$-0.64
$0.65
Q4 24
$-0.57
$0.54
Q3 24
$-0.61
$0.73
Q2 24
$-0.88
$0.75
Q1 24
$-1.01
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
WAFD
WAFD
Cash + ST InvestmentsLiquidity on hand
$417.3M
$734.9M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
$3.0B
Total Assets
$562.2M
$27.3B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
WAFD
WAFD
Q4 25
$417.3M
$734.9M
Q3 25
$401.8M
$657.3M
Q2 25
$381.1M
$809.3M
Q1 25
$407.9M
$1.2B
Q4 24
$291.4M
$1.5B
Q3 24
$317.0M
$2.4B
Q2 24
$323.6M
$2.5B
Q1 24
$298.5M
$1.5B
Total Debt
TARS
TARS
WAFD
WAFD
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
TARS
TARS
WAFD
WAFD
Q4 25
$343.4M
$3.0B
Q3 25
$335.1M
$3.0B
Q2 25
$332.6M
$3.0B
Q1 25
$342.5M
$3.0B
Q4 24
$224.5M
$3.0B
Q3 24
$237.5M
$3.0B
Q2 24
$252.2M
$3.0B
Q1 24
$275.2M
$2.9B
Total Assets
TARS
TARS
WAFD
WAFD
Q4 25
$562.2M
$27.3B
Q3 25
$534.6M
$26.7B
Q2 25
$495.0M
$26.7B
Q1 25
$500.8M
$27.6B
Q4 24
$377.0M
$27.7B
Q3 24
$376.3M
$28.1B
Q2 24
$376.8M
$28.6B
Q1 24
$349.3M
$30.1B
Debt / Equity
TARS
TARS
WAFD
WAFD
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
WAFD
WAFD
Operating Cash FlowLast quarter
$19.3M
$60.5M
Free Cash FlowOCF − Capex
$13.0M
$50.0M
FCF MarginFCF / Revenue
8.6%
26.1%
Capex IntensityCapex / Revenue
4.2%
5.5%
Cash ConversionOCF / Net Profit
0.94×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M
$377.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
WAFD
WAFD
Q4 25
$19.3M
$60.5M
Q3 25
$18.3M
$237.0M
Q2 25
$-29.4M
$58.0M
Q1 25
$-20.7M
$72.1M
Q4 24
$-22.2M
$49.4M
Q3 24
$-8.7M
$439.2M
Q2 24
$-14.4M
$63.1M
Q1 24
$-37.8M
$169.2M
Free Cash Flow
TARS
TARS
WAFD
WAFD
Q4 25
$13.0M
$50.0M
Q3 25
$16.3M
$208.2M
Q2 25
$-30.4M
$53.1M
Q1 25
$-21.2M
$66.6M
Q4 24
$-22.3M
$43.0M
Q3 24
$-8.9M
$414.6M
Q2 24
$-15.4M
$58.3M
Q1 24
$-38.0M
$164.8M
FCF Margin
TARS
TARS
WAFD
WAFD
Q4 25
8.6%
26.1%
Q3 25
13.8%
110.6%
Q2 25
-29.6%
28.5%
Q1 25
-27.1%
37.0%
Q4 24
-33.5%
25.1%
Q3 24
-18.6%
219.7%
Q2 24
-37.8%
30.0%
Q1 24
-137.5%
95.8%
Capex Intensity
TARS
TARS
WAFD
WAFD
Q4 25
4.2%
5.5%
Q3 25
1.6%
15.2%
Q2 25
1.0%
2.6%
Q1 25
0.8%
3.1%
Q4 24
0.1%
3.8%
Q3 24
0.6%
13.1%
Q2 24
2.5%
2.5%
Q1 24
0.6%
2.6%
Cash Conversion
TARS
TARS
WAFD
WAFD
Q4 25
0.94×
Q3 25
3.91×
Q2 25
0.94×
Q1 25
1.28×
Q4 24
1.05×
Q3 24
7.18×
Q2 24
0.98×
Q1 24
10.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons